Mirum Pharmaceuticals, Inc. Revenue
Mirum Pharmaceuticals, Inc. (MIRM) reported Revenue of $176.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $176.24M, a 37.92% increase year-over-year.
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $159.88M, a 43.28% increase year-over-year.
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $148.93M, a 49.81% increase year-over-year.
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $133.01M, a 47.17% increase year-over-year.
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $521.31M, a 54.74% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $336.89M, a 80.76% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $186.37M, a 141.85% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $77.06M, a 302.66% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $176.24M 10-Q · filed 2026-08-05 | $336.13M 10-Q · filed 2026-08-05 | $485.06M derived: sum of 3 quarters · filed 2026-08-05 | $618.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $159.88M 10-Q · filed 2026-05-06 | $308.81M derived: sum of 2 quarters · filed 2026-05-06 | $441.82M derived: sum of 3 quarters · filed 2026-05-06 | $569.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $148.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $281.94M derived: sum of 2 quarters · filed 2026-02-25 | $409.73M derived: sum of 3 quarters · filed 2026-08-05 | $521.31M 10-K · filed 2026-02-25 |
| 2025-09-30 | $133.01M 10-Q · filed 2025-11-04 | $260.80M derived: sum of 2 quarters · filed 2026-08-05 | $372.38M 10-Q · filed 2025-11-04 | $471.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $127.78M 10-Q · filed 2026-08-05 | $239.37M 10-Q · filed 2026-08-05 | $338.78M derived: sum of 3 quarters · filed 2026-08-05 | $429.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $111.58M 10-Q · filed 2026-05-06 | $211.00M derived: sum of 2 quarters · filed 2026-05-06 | $301.38M derived: sum of 3 quarters · filed 2026-05-06 | $379.25M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $99.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $189.79M derived: sum of 2 quarters · filed 2026-02-25 | $267.67M derived: sum of 3 quarters · filed 2026-02-25 | $336.89M 10-K · filed 2026-02-25 |
| 2024-09-30 | $90.38M 10-Q · filed 2025-11-04 | $168.25M derived: sum of 2 quarters · filed 2025-11-04 | $237.47M 10-Q · filed 2025-11-04 | $307.03M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $77.88M 10-Q · filed 2025-08-06 | $147.10M 10-Q · filed 2025-08-06 | $216.65M derived: sum of 3 quarters · filed 2026-02-25 | $264.38M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $69.22M 10-Q · filed 2025-05-07 | $138.78M derived: sum of 2 quarters · filed 2026-02-25 | $186.50M derived: sum of 3 quarters · filed 2026-02-25 | $224.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $69.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $117.28M derived: sum of 2 quarters · filed 2026-02-25 | $154.78M derived: sum of 3 quarters · filed 2026-02-25 | $186.37M 10-K · filed 2026-02-25 |
| 2023-09-30 | $47.73M 10-Q · filed 2024-11-12 | $85.22M derived: sum of 2 quarters · filed 2024-11-12 | $116.82M 10-Q · filed 2024-11-12 | $144.73M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $37.50M 10-Q · filed 2024-08-07 | $69.09M 10-Q · filed 2024-08-07 | $97.00M derived: sum of 3 quarters · filed 2025-02-26 | $115.78M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $31.60M 10-Q · filed 2024-05-08 | $59.50M derived: sum of 2 quarters · filed 2025-02-26 | $78.28M derived: sum of 3 quarters · filed 2025-02-26 | $95.77M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $27.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $46.69M derived: sum of 2 quarters · filed 2025-02-26 | $64.17M derived: sum of 3 quarters · filed 2025-02-26 | $77.06M 10-K · filed 2025-02-26 |
| 2022-09-30 | $18.78M 10-Q · filed 2023-11-02 | $36.26M derived: sum of 2 quarters · filed 2023-11-02 | $49.16M 10-Q · filed 2023-11-02 | $52.29M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | $17.48M 10-Q · filed 2023-08-07 | $30.38M 10-Q · filed 2023-08-07 | $33.51M derived: sum of 3 quarters · filed 2024-03-15 | $38.51M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | $12.89M 10-Q · filed 2023-05-04 | $16.03M derived: sum of 2 quarters · filed 2024-03-15 | $21.03M derived: sum of 3 quarters · filed 2024-03-15 | $32.03M derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $8.14M derived: sum of 2 quarters · filed 2024-03-15 | $19.14M derived: sum of 3 quarters · filed 2024-03-15 | $19.14M 10-K · filed 2024-03-15 |
| 2021-09-30 | $5.00M 10-Q · filed 2022-11-09 | $16.00M derived: sum of 2 quarters · filed 2022-11-09 | $16.00M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $11.00M 10-Q · filed 2022-08-04 | $11.00M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |